Pluri Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
PLUR$1.12-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Statements of Operations (Unaudited)
U.S. Dollars in thousands (except share and per share data)
| Three months ended September 30, | |||
|---|---|---|---|
| Note | 2024 | 2023 | |
| Revenues | $326 | $54 | |
| Cost of revenues | (126) | - | |
| Gross profit | 200 | 54 | |
| Operating expenses: | |||
| Research and development expenses | $(3,392) | $(3,366) | |
| Less: participation by the National Institute of Allergy and Infectious Diseases, or NIAID, the Israeli Innovation Authority, or IIA, Horizon Europe and other parties | 503 | 373 | |
| Research and development expenses, net | (2,889) | (2,993) | |
| General and administrative expenses | (2,509) | (2,438) | |
| Operating loss | (5,198) | (5,377) | |
| Other financial income (expenses), net | 6 | (621) | 493 |
| Interest expenses | (217) | (214) | |
| Total financial income (expenses), net | (838) | 279 | |
| Net loss | $(6,036) | $(5,098) | |
| Net loss attributed to non-controlling interest | $(154) | $(137) | |
| Net loss attributed to shareholders | $(5,882) | $(4,961) | |
| Loss per share: | |||
| Basic and diluted net loss per share | $(1.08) | $(0.96) | |
| Weighted average number of shares used in computing basic and diluted net loss per share (**) | 5,459,236 | 5,166,471 | |
| (**) | See note 5(1) regarding reverse share split |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.